Nakamura Masaru, Koizumi Tomonobu, Hayasaka Munehara, Yasuo Masanori, Tsushima Kenji, Kubo Keishi, Gomi Kotaro, Shikama Naoto
First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, Nagano, 390-8621, Japan.
Cancer Chemother Pharmacol. 2009 May;63(6):1091-6. doi: 10.1007/s00280-008-0837-0. Epub 2008 Sep 26.
Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).
A total of 34 patients aged less than 75 years old with locally advanced stage III NSCLC were enrolled. The patients received intravenous infusions of cisplatin (80 mg/m(2); day 1) and docetaxel (20 mg/m(2); days 1, 8, 15), followed by a week's drug-free interval. Standard concurrent thoracic radiotherapy was given for 6 weeks (2 Gy per fraction; total dose, 60 Gy).
Over Grade 3 neutropenia, esophagitis and pulmonary toxicities were observed in 23.5, 17.6 and 11.8% of the cases, respectively. One complete response and 20 partial responses were obtained, with an objective response rate of 61.8%. The median survival time was 26.4 months (95% CI 16.9--not reached) and the 1- and 3-year survival rates were 76.5 and 41.2%, respectively.
Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.
我们的目标是评估顺铂联合每周分次剂量多西他赛同步放化疗对Ⅲ期非小细胞肺癌（NSCLC）患者的疗效和毒性。
共纳入34例年龄小于75岁的局部晚期Ⅲ期NSCLC患者。患者接受顺铂静脉输注（80mg/m²；第1天）和多西他赛（20mg/m²；第1、8、15天），随后有1周的无药间隔期。给予标准的同步胸部放疗6周（每次分割剂量2Gy；总剂量60Gy）。
分别有23.5%、17.6%和11.8%的病例出现3级以上中性粒细胞减少、食管炎和肺部毒性。获得1例完全缓解和20例部分缓解，客观缓解率为61.8%。中位生存时间为26.4个月（95%CI 16.9 - 未达到），1年和3年生存率分别为76.5%和41.2%。
顺铂联合每周多西他赛同步放疗是局部晚期NSCLC的一种可行且有效的治疗方案。
